Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

Elsevier
Publish with us
AI-Generated response:

How does renal or hepatic impairment affect Heparin dosing?

Answer generated on June 4, 2024

The AI-generated responses are for illustration purposes only and should not be used for medical purposes.

In patients with renal or hepatic impairment, unfractionated heparin should be used cautiously due to decreased clearance and increased risk of bleeding.

Dose adjustments and close monitoring are recommended.

  • Unfractionated heparin is preferred in patients with severe renal impairment (creatinine clearance less than 30 mL/min) as low-molecular-weight heparins (LMWHs) are primarily eliminated by the kidneys and may accumulate, increasing the risk of bleeding.[1-2]

  • In patients with hepatic impairment, the clearance of unfractionated heparin may also be decreased, necessitating careful monitoring and potential dose adjustments to avoid excessive anticoagulation and bleeding.[1]

  • Monitoring of anti-factor Xa levels may be considered in patients with severe renal impairment to ensure therapeutic levels and avoid toxicity.[3]

  • For patients with mild to moderate renal impairment, dose adjustments or careful monitoring might be necessary depending on the severity of the impairment.[2]

  • In patients with hepatic disease, especially those with conditions like cirrhosis, there is an increased risk of bleeding due to coagulopathies; thus, heparin should be used with caution and under close monitoring.[1-2]

Additional info

When managing patients with renal or hepatic impairment, it is crucial to consider the altered pharmacokinetics of heparin. Both renal and hepatic dysfunctions can lead to reduced clearance of heparin, resulting in higher plasma levels and prolonged effects, which significantly increases the risk of bleeding. This necessitates a careful approach to dosing, with adjustments based on the degree of impairment and continuous monitoring of coagulation parameters to ensure safety. The use of unfractionated heparin is generally safer in these populations due to its shorter half-life and easier reversibility compared to LMWHs. Regular monitoring of aPTT (activated partial thromboplastin time) or anti-factor Xa levels can help guide therapy to maintain efficacy while minimizing the risk of adverse effects. In clinical practice, collaboration with a nephrologist or hepatologist may be beneficial in managing these complex cases, ensuring that the anticoagulation therapy is both effective and safe.

References

Reference 1

1.

Heparin, Elsevier ClinicalKey Drug Monograph Content last updated: May 1, 2024

Contraindications And Precautions Use heparin cautiously in patients with underlying hepatic disease as these patients often have coagulopathies and are at increased risk for anticoagulant-associated bleeding. Patients with inherited antithrombin deficiency usually have antithrombin concentrations 40% to 60% of normal but may have resistance to heparin and require higher doses to achieve the desired therapeutic response. Patients with acquired antithrombin deficiency, as seen with severe hepatic disease (e.g., cirrhosis), renal disease (e.g., nephrotic syndrome), or disseminated intravascular coagulation (DIC), may not respond to heparin.

Pharmacokinetics Subcutaneous heparin concentrations reach steady-state between 4 and 10 hours. **• Special Populations** **Hepatic Impairment** The rate of clearance of unfractionated heparin may be decreased in persons with hepatic impairment and plasma heparin concentrations may be higher compared to persons with normal hepatic function. **Renal Impairment** The rate of clearance of unfractionated heparin may be decreased in persons with renal impairment and plasma heparin concentrations may be higher compared to persons with normal renal function. **Pediatrics** Neonates Premature neonates (n = 25, gestational age 25 to 36 weeks) had a significantly shorter plasma half-life (35.5 to 41.6 minutes), larger volume of distribution (57.8 to 81 mL/kg), and faster clearance (1.37 to 1.49 mL/kg/minute) after an IV bolus dose of 100 units/kg compared to adults receiving an IV bolus dose of 75 units/kg (half-life = 63.3 minutes, Vd = 36.6 mL/kg, CL = 0.43 mL/kg/minute). **Geriatric** Persons older than 60 years may have higher plasma concentrations of heparin and longer activated partial thromboplastin times (aPTTs) compared with younger persons after similar doses of heparin.

Reference 2

2.

Deep Vein Thrombosis, Elsevier ClinicalKey Clinical Overview

Treatment Patients with chronic kidney disease Unfractionated heparin is recommended for patients with acute venous thromboembolism and severe renal failure Use of low-molecular-weight heparin is controversial in patients with kidney disease owing to bleeding risk, but it may be acceptable for some patients with lesser degrees of renal insufficiency. If used, administer under guidance of a nephrologist For maintenance and, if indicated, extended treatment of venous thromboembolism, warfarin is the preferred anticoagulant in patients with severe renal disease Though direct oral anticoagulants are attractive alternatives to warfarin therapy, large-scale clinical trials of direct oral anticoagulants in treatment of venous thromboembolism excluded patients with severe kidney disease so safety in these patients and those on dialysis is not well-characterized Accumulating data (largely from atrial fibrillation experience) suggest that direct oral anticoagulants are safe and effective in severe kidney disease, including end-stage kidney disease; most studies in this setting have focused on apixaban. If used, administer under guidance of a nephrologist For lesser degrees of renal dysfunction, use of direct oral anticoagulants may be reasonable; dose reduction may be necessary Patients with cirrhosis These patients have bleeding coagulopathy due to defective coagulation factor synthesis but can also be in a hypercoagulable state due to decreased antithrombin III, protein C, and protein S activity, leading to portal vein thrombosis and other venous thromboembolism events

Treatment Table Title: Anticoagulation agents for special populations. Table Caption: Abbreviations: BMI: body mass index; DOAC: direct oral anticoagulant; DVT, deep vein thrombosis; IV, intravenous; VTE, venous thromboembolism. Table Heads: Special population| Preferred drug| Discussion points Table Rows: Patients with malignancy| DOAC (rivaroxaban, apixaban or edoxaban) or low- molecular-weight heparin| Efficacy for acute and extended therapy similar between low-molecular-weight heparin and DOACs; however, DOACs are associated with greater risk of bleeding in gastrointestinal and genitourinary cancers Pregnant patients| Low-molecular-weight heparin| Warfarin is contraindicated Children| Low-molecular-weight heparin and warfarin| Dabigatran and rivaroxaban both approved for use in children after at least 5days of parenteral anticoagulant Patients with acute kidney injury or chronic kidney disease| IV unfractionated heparin, followed by warfarin, is suggested for initial anticoagulation with severe renal failure DOACs may be used cautiously for mild to moderate renal insufficiency | Unfractionated heparin is preferred for severe renal failure with creatinine clearance less than 30 mL/minute Use of DOACs in renal dysfunction requires dose reduction or avoidance depending on the particular agent Patients with cirrhosis| Low-molecular-weight heparin| Low-molecular-weight heparin is preferred over warfarin owing to difficulty in relying on INR to monitor warfarin dosing Patients with heparin-induced thrombocytopenia| Argatroban| Subcutaneous

Reference 3

3.

Low Molecular Weight Heparins (LMWHs), Elsevier ClinicalKey Drug Class Overview Content last updated: January 1, 2012

LMWHs are excreted via the kidney; therefore, delayed elimination and subsequent accumulation may occur in patients with renal impairment. Patients with renal impairment should be observed for signs and symptoms of bleeding during LMWH therapy. Anti-factor Xa monitoring may be considered in patients with severe renal impairment to avoid toxicity and ensure therapeutic concentrations. In patients with a CrCl < 30ml/min, tinzaparin and dalteparin use is not recommended; however, enoxaparin has been studied in this population and dose adjustment recommendations are available. In a study comparing enoxaparin and tinzaparin for 8 days in 55 elderly patients with CrCl between 20 and 50 ml/min, enoxaparin was found to accumulate, but tinzaparin did not[50260].

Follow up questions